We are at a critical juncture in the pandemic: an increasing portion of the population has been vaccinated and the economy is beginning to snap back, but new variants and the long-term effects of Covid may threaten these hard-won successes.
Led by CNBC’s anchors and reporters, this CNBC Healthy Returns Summit will take stock of all that we have learned over the past 15 months – from vaccines to health equity and mental health – and apply it to future treatments and innovations. It will also look at the new ideas and breakthroughs on the horizon that are sure to transform the health care industry for years to come.
WHO SHOULD ATTEND: Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
PAST EVENTS: 2020 | 2019 | 2018
Watch our 2020 Event Highlights
Visit cnbc.com/healthy-returns to find in-depth coverage from the CNBC team about health care innovation.
Martin Luther King, Jr. Community Hospital
Dr. Elaine Batchlor is Chief Executive Officer of Martin Luther King, Jr. Community Hospital.
Dr. Elaine Batchlor is the chief executive officer of Martin Luther King, Jr. Community Hospital, which opened in 2015. Dr. Batchlor was the driving force behind the effort to open the new, state-of-the-art, community-oriented, safety-net hospital providing compassionate, quality care and improving the health of the South Los Angeles community.
Throughout her career, Dr. Batchlor’s number one priority has been to improve access and quality of care for underserved communities utilizing innovative and collaborative approaches. Her work to increase access for underserved populations has been recognized as an example of leading best practices and adopted throughout California.
Before assuming the helm of Martin Luther King, Jr. Community Hospital, Dr. Batchlor served on the executive leadership team of L.A. Care Health Plan, the nation’s largest public health plan. As chief medical officer, she was instrumental in developing a care delivery model that expanded access and resources to more than a million individuals throughout the county.
She spearheaded provider use of information technology and telemedicine to improve access and quality of care for Los Angeles County’s Medi-Cal (Medicaid) population. Under her leadership, L.A. Care established the Health Information Technology Extension Center, becoming the second health plan in the nation to operate a Regional Extension Center to help safety-net providers adopt and use electronic health records. She implemented eConsult, an innovative electronic physician-to-specialist consultation and referral system, for Los Angeles County community health centers and the Los Angeles County Department of Health Services.
Prior to L.A. Care, Dr. Batchlor served in leadership positions at the California HealthCare Foundation, the Los Angeles County Department of Health Services, Prudential Health Care, and Ross Loos Medical Group. Early in her career she served as a clinical instructor at the UCLA School of Medicine.
Dr. Batchlor is an active community volunteer, serving on multiple community and healthcare boards. She has a particular interest in mentoring youth. She regularly meets with students, from high school through professional school, who are interested in careers in healthcare. Formerly, she served on advisory boards for the UCLA Fielding School of Public Health, the UCLA National Clinical Scholars, and the UCLA Academic Advancement Program Advisory Council. Recently, she was elected to the National Academy of Medicine, an academy committed to the health for all by advancing science, accelerating health equity, and providing independent, authoritative, and trusted advice nationally and globally. A Harvard alumna, Dr. Batchlor serves as an interviewer for Harvard College applicants and as a liaison to a local high school.
She served as the past chair and is currently on the board of the Integrated Healthcare Association. She is a member of the Board of Trustees of the California Association of Hospitals and Health Systems, the boards of directors of the Healthcare Quality Institute and California Health and Wellness, and the editorial board of Health Affairs, the leading peer-reviewed journal of health policy thought and research.
Dr. Batchlor received a Bachelor of Arts degree from Harvard University, a Master of Public Health degree from the University of California, Los Angeles, and a Doctorate in Medicine degree from Case Western Reserve University. She completed internship, residency, and fellowship training in internal medicine and rheumatology at Harbor-UCLA Medical Center and is board-certified in both specialties.
She is married to a lawyer who has spent his career representing indigent clients, currently working for the Los Angeles County Public Defender’s Office. The couple has twin boys.
Pfizer
Kathrin Jansen is SVP, Head of Vaccine Research and Development at Pfizer.
Kathrin U. Jansen, PhD, is Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and a member of Pfizer’s Worldwide Research and Development leadership team. Dr. Jansen oversees a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to registration and post-marketing commitments of first-in-class or best-in-class vaccines to prevent or treat diseases of significant unmet medical need. More recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B. Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany. Following completion of her formal training, she continued her postdoctoral training at Cornell University working on the structure and function of the acetylcholine receptor. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland, where she focused on basic studies of a receptor believed to be a drug target to treat allergies. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth’s Research and Development Executive Committee since 2006 and was responsible for vaccine discovery, early development and clinical testing operations. Dr. Jansen also briefly worked at Vaxgen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for the company’s late stage development programs. Prior to joining Vaxgen, Dr. Jansen spent 12 years at Merck Research Laboratories where she directed or supported a number of vaccine efforts, including Merck’s novel bacterial vaccine programs and viral vaccine programs (rotavirus, zoster and mumps, measles and rubella). Dr. Jansen initiated and led the development of Gardasil®, the world’s first cervical cancer vaccine.
Eli Lilly and Company
Dave Ricks is Chairman and CEO of Eli Lilly and Company.
Dave Ricks is chairman and chief executive officer of Eli Lilly and Company. He became CEO in January 2017 and was elected chairman of the company’s board effective June 2017.
A Lilly veteran for more than 20 years, Dave served as president of Lilly Bio-Medicines from 2012 to 2016. Previously, he was president of Lilly USA, the company’s largest affiliate, from 2009 to 2012. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. And he was general manager of Lilly Canada from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.
Dave earned a bachelor of science degree from Purdue University in 1990 and a master of business administration degree from Indiana University in 1996.
Dave is on the board of Adobe and is chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). He also serves on the board of the Central Indiana Corporate Partnership. Dave is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). He serves on the Riley Children’s Foundation’s board of governors.
Dalio Center for Health Justice, NewYork-Presbyterian
Julia Iyasere is Vice President of Dalio Center for Health Justice at NewYork-Presbyterian.
A native of California, Dr. Iyasere moved to the East Coast to attend Yale University where she graduated with a B.S. in Molecular Biology with a focus in Neuroscience. After a year working in cancer cell biology and cell signaling cascades at Harvard Medical School, she joined the Columbia community at Columbia College of Physician and Surgeons, eventually choosing to pursue a dual degree with the Columbia Business School and graduating with an M.D./M.B.A in 2008. After completing her residency in Internal Medicine at Columbia, Dr. Iyasere stayed for a year as Chief Resident before joining the Section of Hospital Medicine in 2012. She completed a part-time fellowship in Medical Simulation at the NYPresbyterian Simulation Center during her first year with the Division. Currently, Dr. Iyasere is the Director of LEAD Academy, a physician leadership and career development program at NewYork-Presbyterian Hospital. She also serves as the Associate DIO for GME and Associate Program Director for the Columbia Internal Medicine Residency Program.
Section 32
Bill Maris is Founder of Section 32.
Bill Maris is the founder of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences.
Bill is the founder and first CEO of Google Ventures.
In the last 10 years, Bill has managed over $5 billion in venture investments in over 400 companies including Auris, Aurora Innovations, Carbon 3D, The Climate Corporation, Crowdstrike, Duo Security, Flatiron Health, Foundation Medicine, Impossible Foods, Nest, Slack, Uber, and Robinhood. These investments have resulted in more than 20 IPOs, 100+ mergers and acquisitions and 40+ companies that have exceeded $1B valuations.
While at Google, Bill was also Vice President of Special Projects where he worked closely with Waymo, Google X and Verily, was head of Google for Startups and led private company investment activities for the company while building a team of 70 across 13 global offices, 8 countries and 9 different venture funds. Bill is also the creator and founder of Calico, a multi-billion dollar company focused on understanding aging and extending life.
Previously, Bill has worked in biotechnology private equity with Sweden’s Investor AB and is the founder of one of the world’s first web-hosting companies, Burlee.com, now part of Web.com.
In the mid-2000s, he partnered with entrepreneur David Green to transfer a novel hydrophobic acrylic lens to Aurolab to treat and cure cataract blindness in the developing world. It has since helped prevent or cure cataract blindness in more than 30 million people worldwide.
Bill has a degree in neuroscience from Middlebury College and his background includes research at the Duke University School of Medicine, Department of Neurobiology.
Blackstone Life Sciences
Nicholas Galakatos is Senior Managing Director of Blackstone Life Sciences.
Nicholas Galakatos is the Global Head of Life Sciences and is the Chairman of its Investment Committee, having joined Blackstone as part of its acquisition of Clarus in December 2018.
Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception in 2005. Dr. Galakatos has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage companies. Before Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm. From 1997 to 2000 he was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO. Dr. Galakatos is the Chairman of Anthos Therapeutics and a member of the Board of Directors of Praxis (NASDAQ: PRAX) and Talaris, Inc. He is a member of the Director's Council of the Koch Institute at MIT and a member of the Board of Trustees at Reed College. He is also on the Board of Directors of BioMed Realty.
Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School. He earned his undergraduate degree at Reed College.
Teladoc Health
Jason Gorevic is CEO and a Member of the Board of Directors of Teladoc Health.
Jason Gorevic is chief executive officer and a member of Teladoc Health's board of directors. Since taking the reins in 2009, he has led Teladoc Health to its position today as the world leader in virtual care, achieving significant growth in revenue, membership, and telehealth utilization. Under his leadership the company has established a proven track record of successfully shaping the market and driving healthcare transformation by executing on the strategic vision, delivering award-winning innovation, and effectively integrating each corporate acquisition.Nationally recognized as a thought leader and trailblazer in the virtual delivery of healthcare, Mr. Gorevic is fueled by a passion for improving healthcare outcomes and providing universal access to care. His extensive career in healthcare began at Oxford Health, and he has also held executive leadership roles at WellPoint, Inc. (now Anthem, Inc.) and Empire BlueCross BlueShield.He holds a Bachelor of Arts in International Relations from the University of Pennsylvania.
Massachusetts General Hospital
Sharmin Ghaznavi, MD, PhD, is Associate Director and Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital.
Sharmin Ghaznavi, MD, PhD, is the Associate Director and the Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital. Dr. Ghaznavi also serves as a psychiatrist at the MGH Dauten Family Center for Bipolar Treatment Innovation and is an instructor in Psychiatry at Harvard Medical School. Her research interests are the neural correlates of cognitive processes underlying mental illness. Dr. Ghaznavi has been the recipient of the Dupont-Warren and Livingston psychiatric research fellowships from Harvard Medical School and a 2012 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation.
Dr. Ghaznavi received her undergraduate degrees in biology, brain and cognitive sciences, and philosophy from the Massachusetts Institute of Technology. She obtained her medical degree and PhD in neuroscience from Yale University and completed a residency in adult psychiatry at the Mass General/McLean Psychiatry Residency Program. As a resident, Dr. Ghaznavi received the Thomas P. Hackett award for academic and research excellence and the Joyce Tedlow Award from the mood and anxiety disorders board for efforts to integrate psychotherapy, psychopharmacology and research.
Daniel Carcillo is CEO and Co-founder of Wesana Health and a former NHL player.
Daniel Carcillo is the CEO and Co-founder of Wesana Health, an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Prior to launching Wesana, Daniel was a professional hockey player who won two Stanley Cup Championships with the Chicago Blackhawks before being forced to retire at the age of 30 due to post-concussion syndrome. In the years following his professional hockey career, Carcillo has been steadfastly focused on researching and developing natural-sourced neurological treatment regimens to treat TBI. Daniel is a leading advocate for the emerging psychedelics space and sits on the board of the Heroic Hearts Project, a registered 501(c)(3) non-profit that connects military veterans struggling with mental trauma to psychedelic therapy options including ayahuasca, psilocybin and ketamine.
Christian Angermayer is Founder of Apeiron Investment Group
Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and asset management business. Apeiron’s areas of focus are Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has deep experience and a proven track record of more than 20 years. Apeiron has a global approach and deploys capital with a team of more than 20 investment professionals over seven strategies. As the investment group is investing predominantly its own capital, they are entrepreneurial, reliable & flexible, and a true, long term partner for all portfolio companies. Apeiron invests across the entire company lifecycle, starting from seed/startup investments to large-scale growth rounds as well as investments into listed companies.
Rochelle Walensky is Director of the CDC.
Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.
Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities.
Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.
She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.
Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.
Steven J. Corwin, MD, is President and CEO of NewYork-Presbyterian.
Steven J. Corwin, MD, is President and Chief Executive Officer of NewYork-Presbyterian, one of the nation’s largest, most comprehensive healthcare delivery systems.
Under Dr. Corwin’s leadership, NewYork-Presbyterian has nearly doubled in size and now comprises more than 47,000 employees and affiliated physicians, dedicated to providing world-class care during nearly 6 million patient visits each year at 10 hospitals as well as 200 primary and specialty care clinics and medical practices across the Greater New York area. Together with two distinguished medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, NewYork-Presbyterian provides high-quality, compassionate care, pursues clinical excellence, engages in pioneering medical research, and provides outstanding medical education to the next generation of doctors. NewYork-Presbyterian Hospital, the seven-campus academic medical center, is ranked No. 4 in the nation and has been the top-ranked hospital in New York for 20 consecutive years, according to U.S. News and World Report’s annual rankings of “Best Hospitals.”
As President and CEO, Dr. Corwin has embraced innovative approaches to patient-centered care. He led the way in establishing the NewYork-Presbyterian Regional Hospital Network and NewYork-Presbyterian Medical Groups, which enable patients to receive NewYork-Presbyterian’s world-renowned care in their own communities. He has launched a number of groundbreaking initiatives, including NYP OnDemand, a digital suite of telehealth services that increases access to NewYork-Presbyterian’s world-class care, and the East Coast’s first Mobile Stroke Treatment Unit, which provides fast, specialized care to patients who may be having a stroke and expanded this service to Brooklyn and Queens. He has also overseen the development of the NewYork-Presbyterian David H. Koch Center, a state-of-the-art ambulatory care facility that offers a patient experience that is second to none.
Healthcare quality has been a major focus of his tenure. For the third consecutive year, NewYork-Presbyterian Hospital is the only hospital in the nation with statistically better 30-day mortality rates in all six medical conditions measured by the Centers for Medicare and Medicaid Services (CMS). Those conditions are: heart failure, pneumonia, COPD, heart attack, stroke and coronary artery bypass graft.
Recognizing that engaging physicians is crucial to NewYork-Presbyterian’s success, Dr. Corwin has launched a series of initiatives to improve communication, address barriers to physician work, and encourage input from physicians on strategic development. He also launched the LEAD Attending Program (Leadership, Education and Development) for young attending physicians interested in careers that include healthcare administration.
He has championed a Respect initiative that encourages employees to work together as a team to provide the highest quality care to patients while also treating each other with respect and a Diversity and Inclusion initiative. As part of his commitment to employees, he instituted the most comprehensive paid parental leave policy of its kind among New York City hospitals and healthcare systems.
Prior to his appointment as CEO, Dr. Corwin served as NewYork-Presbyterian Hospital’s Executive Vice President and Chief Operating Officer, where he oversaw day-to-day operations across five campuses. Dr. Corwin joined the NewYork-Presbyterian team in 1979. From 1998 to 2005, he was the organization’s Senior Vice President and Chief Medical Officer.
Dr. Corwin is Immediate Past Chairman of the Health Care Systems Council of the American Hospital Association, Past Chairman of the Healthcare Association of New York State, and Past Chairman of the Greater New York Hospital Association. He remains on the board of each of these organizations and is a Board Member at the New York Academy of Medicine. In addition, he is a member of the Citizens’ Committee for Children of New York’s Corporate Advisory Council, the Association for a Better New York’s Census 2020 Committee, and a member of the Mayor’s Fund Board of Advisors. In 2020, the Foreign Policy Association awarded Dr. Corwin its highest honor, the Foreign Policy Association Medal, in recognition of his work to expand public knowledge of responsible internationalism. Also in 2020, Dr. Corwin was inducted into the Crain’s New York Business Hall of Fame.
A cardiologist and internist, Dr. Corwin obtained his undergraduate and medical degrees from Northwestern University, graduating summa cum laude and with Alpha Omega Alpha honors. He completed both his internal medicine residency and cardiology training at Columbia-Presbyterian Medical Center.
Michael Neidorff is Chairman, President and CEO of Centene Corporation.
Michael Neidorff is Centene Corporation's chairman, president and chief executive officer. A recognized leader in the industry, he is committed to building a multi-national healthcare enterprise while upholding Centene's local approach to healthcare. He demonstrates a history of successfully implementing programs and services under Medicaid, Medicare, and commercial managed care. Under his leadership, Centene has grown from a $40 million corporation to a publicly traded (NYSE: CNC), FORTUNE® 100, diversified, healthcare enterprise.
Michael Neidorff became president and chief executive officer of Centene Corporation in 1996. The company established operations in all 50 states – to become the largest Medicaid managed care organization in the U.S. and the top insurer in the Health Insurance Marketplace. Revenues are expected to exceed $114 billion in 2021. Centene now delivers high-quality and accessible healthcare to nearly 1 in 15 individuals across the nation.
Centene provides accessible, cost-effective coverage to the rising number of under-insured and uninsured people in communities across the U.S. Under Mr. Neidorff's leadership, Centene has expanded from operating Medicaid health plans solely in Wisconsin and Indiana, to operations in every state, serving more than 25 million managed care and TRICARE eligible individuals.
Mr. Neidorff's record of transformative leadership is proven in the healthcare industry. In 1985, he started Physicians Health Plan of Greater St. Louis, a subsidiary of UnitedHealth Group. He served as the president and chief executive officer from 1985-1995, and grew the plan to be one of UnitedHealth Group's most successful and profitable plans in the country. From 1995-1996, he served as the regional vice president of Coventry Health Care, Inc., a publicly traded managed care organization, and as the president and chief executive officer of one of its subsidiaries, Group Health Plan Inc. in St. Louis. He also served in international senior executive positions at Miles Laboratories/Bayer AG.
Michael Neidorff dedicates significant time to civic organizations. He is a board member of the National Urban League and served as its chairman from 2014-2019. In 2015, he was inducted into the Hall of Fame for Junior Achievement of Greater St. Louis. He served as a member of the board of directors for the Greater St. Louis Boy Scouts of America since 1990, serving as Pathfinder district chair, vice chairman and chairman of the Special Needs Committee, vice president of Finance, and council president. Mr. Neidorff is a member of the board of trustees for Trinity University in San Antonio, Texas, his alma mater, and previously served as chairman of the board.
Community Involvement and Recognition
Having an appreciation for the arts, Mr. Neidorff is also involved with several major arts institutions. He sits on the board of the St. Louis Symphony Orchestra, where he previously served a term as chairman and is currently a trustee on its Endowment Committee. As a trustee for the Opera Theatre of St. Louis, he serves on the Institutional Development Committee and previously served as a vice chairman. Mr. Neidorff serves as Treasurer of the John F. Kennedy Center for the Performing Arts Board of Trustees and member of the International Committee on the Arts. He previously served the Kennedy Center as a 2005 trustee, vice chairman of its Fund Board, chairman of the Education Committee, and co-chair of the International Committee on the Arts.
Michael Neidorff has been recognized by multiple organizations for his business leadership as well as his community and civic involvement. He was named one of the "100 Most Influential People in Healthcare" by Modern Healthcare magazine in 2018 and 2019. In January 2020, he and his wife, Noémi Neidorff, received the Whitney M. Young Humanitarian Award from the Urban League of Metropolitan St. Louis and Saint Louis University. In 2019, he was honored at the St. Louis Business Journal's C-Suite Awards for his contributions to business and the St. Louis community. He was honored with the St. Louis Post-Dispatch Citizen of the Year Award in 2017.
Mr. Neidorff holds a bachelor's degree from Trinity University and a master's degree from St. Francis College. He lives in St. Louis, with his wife, Noémi. They have two children.
Vicki Sato is a Chairman of the Board of Directors at Vir Biotechnology and Denali Therapeutics.
Vicki Sato, Ph.D., serves as chairman of the board of directors at Vir Biotechnology and Denali Therapeutics. She is a business advisor to enterprises in the biotechnology and pharmaceutical industries. From 2006-2017, Dr. Sato served on the faculties of Harvard University: as Professor of Management Practice at The Harvard Business School and as Professor of the Practice, Molecular and Cell Biology, on the Faculty of Arts and Sciences.
Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs in the areas of virology, inflammation and cystic fibrosis. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and where she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board.
In addition to chairing the boards of Denali Therapeutics and Vir Biotechnology, Dr. Sato serves as a member of the board of directors of publicly held Akouos. She has previously served on the boards of Bristol Myers Squibb, where she served as lead independent director, BorgWarner Corporation, PerkinElmer Corporation, Alnylam, and Syros Pharmaceuticals. In 2018, she was the recipient of an Outstanding Director award from the National Association of Corporate Directors. Dr. Sato is a member of the Board of Advisors of the Isabella Stewart Gardner Museum in Boston, MA, and Co-Chairs the Advisory Council on LifeSciences for the New York City Economic Development Council.
She received her A.B. from Radcliffe College and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California, Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
Meg Tirrell is a general assignment reporter at CNBC, focusing on biotechnology and pharmaceuticals.
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Bertha Coombs is a reporter for CNBC.
Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
Tyler Mathisen is the co-anchor of "Power Lunch" & Vice President, Events Strategy for CNBC.
Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
Martin Luther King, Jr. Community Hospital
Read Bio ⟶Dr. Elaine Batchlor is the chief executive officer of Martin Luther King, Jr. Community Hospital, which opened in 2015. Dr. Batchlor was the driving force behind the effort to open the new, state-of-the-art, community-oriented, safety-net hospital providing compassionate, quality care and improving the health of the South Los Angeles community.
Throughout her career, Dr. Batchlor’s number one priority has been to improve access and quality of care for underserved communities utilizing innovative and collaborative approaches. Her work to increase access for underserved populations has been recognized as an example of leading best practices and adopted throughout California.
Before assuming the helm of Martin Luther King, Jr. Community Hospital, Dr. Batchlor served on the executive leadership team of L.A. Care Health Plan, the nation’s largest public health plan. As chief medical officer, she was instrumental in developing a care delivery model that expanded access and resources to more than a million individuals throughout the county.
She spearheaded provider use of information technology and telemedicine to improve access and quality of care for Los Angeles County’s Medi-Cal (Medicaid) population. Under her leadership, L.A. Care established the Health Information Technology Extension Center, becoming the second health plan in the nation to operate a Regional Extension Center to help safety-net providers adopt and use electronic health records. She implemented eConsult, an innovative electronic physician-to-specialist consultation and referral system, for Los Angeles County community health centers and the Los Angeles County Department of Health Services.
Prior to L.A. Care, Dr. Batchlor served in leadership positions at the California HealthCare Foundation, the Los Angeles County Department of Health Services, Prudential Health Care, and Ross Loos Medical Group. Early in her career she served as a clinical instructor at the UCLA School of Medicine.
Dr. Batchlor is an active community volunteer, serving on multiple community and healthcare boards. She has a particular interest in mentoring youth. She regularly meets with students, from high school through professional school, who are interested in careers in healthcare. Formerly, she served on advisory boards for the UCLA Fielding School of Public Health, the UCLA National Clinical Scholars, and the UCLA Academic Advancement Program Advisory Council. Recently, she was elected to the National Academy of Medicine, an academy committed to the health for all by advancing science, accelerating health equity, and providing independent, authoritative, and trusted advice nationally and globally. A Harvard alumna, Dr. Batchlor serves as an interviewer for Harvard College applicants and as a liaison to a local high school.
She served as the past chair and is currently on the board of the Integrated Healthcare Association. She is a member of the Board of Trustees of the California Association of Hospitals and Health Systems, the boards of directors of the Healthcare Quality Institute and California Health and Wellness, and the editorial board of Health Affairs, the leading peer-reviewed journal of health policy thought and research.
Dr. Batchlor received a Bachelor of Arts degree from Harvard University, a Master of Public Health degree from the University of California, Los Angeles, and a Doctorate in Medicine degree from Case Western Reserve University. She completed internship, residency, and fellowship training in internal medicine and rheumatology at Harbor-UCLA Medical Center and is board-certified in both specialties.
She is married to a lawyer who has spent his career representing indigent clients, currently working for the Los Angeles County Public Defender’s Office. The couple has twin boys.
Pfizer
Read Bio ⟶Kathrin U. Jansen, PhD, is Senior Vice President and Head of Vaccine Research and Development at Pfizer Inc, and a member of Pfizer’s Worldwide Research and Development leadership team. Dr. Jansen oversees a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to registration and post-marketing commitments of first-in-class or best-in-class vaccines to prevent or treat diseases of significant unmet medical need. More recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B. Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany. Following completion of her formal training, she continued her postdoctoral training at Cornell University working on the structure and function of the acetylcholine receptor. She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland, where she focused on basic studies of a receptor believed to be a drug target to treat allergies. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010. Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth’s Research and Development Executive Committee since 2006 and was responsible for vaccine discovery, early development and clinical testing operations. Dr. Jansen also briefly worked at Vaxgen as Chief Scientific Officer and Senior Vice President for Research and Development with responsibility for the company’s late stage development programs. Prior to joining Vaxgen, Dr. Jansen spent 12 years at Merck Research Laboratories where she directed or supported a number of vaccine efforts, including Merck’s novel bacterial vaccine programs and viral vaccine programs (rotavirus, zoster and mumps, measles and rubella). Dr. Jansen initiated and led the development of Gardasil®, the world’s first cervical cancer vaccine.
Eli Lilly and Company
Read Bio ⟶Dave Ricks is chairman and chief executive officer of Eli Lilly and Company. He became CEO in January 2017 and was elected chairman of the company’s board effective June 2017.
A Lilly veteran for more than 20 years, Dave served as president of Lilly Bio-Medicines from 2012 to 2016. Previously, he was president of Lilly USA, the company’s largest affiliate, from 2009 to 2012. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. And he was general manager of Lilly Canada from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.
Dave earned a bachelor of science degree from Purdue University in 1990 and a master of business administration degree from Indiana University in 1996.
Dave is on the board of Adobe and is chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). He also serves on the board of the Central Indiana Corporate Partnership. Dave is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). He serves on the Riley Children’s Foundation’s board of governors.
Dalio Center for Health Justice, NewYork-Presbyterian
Read Bio ⟶A native of California, Dr. Iyasere moved to the East Coast to attend Yale University where she graduated with a B.S. in Molecular Biology with a focus in Neuroscience. After a year working in cancer cell biology and cell signaling cascades at Harvard Medical School, she joined the Columbia community at Columbia College of Physician and Surgeons, eventually choosing to pursue a dual degree with the Columbia Business School and graduating with an M.D./M.B.A in 2008. After completing her residency in Internal Medicine at Columbia, Dr. Iyasere stayed for a year as Chief Resident before joining the Section of Hospital Medicine in 2012. She completed a part-time fellowship in Medical Simulation at the NYPresbyterian Simulation Center during her first year with the Division. Currently, Dr. Iyasere is the Director of LEAD Academy, a physician leadership and career development program at NewYork-Presbyterian Hospital. She also serves as the Associate DIO for GME and Associate Program Director for the Columbia Internal Medicine Residency Program.
Section 32
Read Bio ⟶Bill Maris is the founder of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences.
Bill is the founder and first CEO of Google Ventures.
In the last 10 years, Bill has managed over $5 billion in venture investments in over 400 companies including Auris, Aurora Innovations, Carbon 3D, The Climate Corporation, Crowdstrike, Duo Security, Flatiron Health, Foundation Medicine, Impossible Foods, Nest, Slack, Uber, and Robinhood. These investments have resulted in more than 20 IPOs, 100+ mergers and acquisitions and 40+ companies that have exceeded $1B valuations.
While at Google, Bill was also Vice President of Special Projects where he worked closely with Waymo, Google X and Verily, was head of Google for Startups and led private company investment activities for the company while building a team of 70 across 13 global offices, 8 countries and 9 different venture funds. Bill is also the creator and founder of Calico, a multi-billion dollar company focused on understanding aging and extending life.
Previously, Bill has worked in biotechnology private equity with Sweden’s Investor AB and is the founder of one of the world’s first web-hosting companies, Burlee.com, now part of Web.com.
In the mid-2000s, he partnered with entrepreneur David Green to transfer a novel hydrophobic acrylic lens to Aurolab to treat and cure cataract blindness in the developing world. It has since helped prevent or cure cataract blindness in more than 30 million people worldwide.
Bill has a degree in neuroscience from Middlebury College and his background includes research at the Duke University School of Medicine, Department of Neurobiology.
Blackstone Life Sciences
Read Bio ⟶Nicholas Galakatos is the Global Head of Life Sciences and is the Chairman of its Investment Committee, having joined Blackstone as part of its acquisition of Clarus in December 2018.
Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception in 2005. Dr. Galakatos has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage companies. Before Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm. From 1997 to 2000 he was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO. Dr. Galakatos is the Chairman of Anthos Therapeutics and a member of the Board of Directors of Praxis (NASDAQ: PRAX) and Talaris, Inc. He is a member of the Director's Council of the Koch Institute at MIT and a member of the Board of Trustees at Reed College. He is also on the Board of Directors of BioMed Realty.
Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School. He earned his undergraduate degree at Reed College.
Teladoc Health
Read Bio ⟶Jason Gorevic is chief executive officer and a member of Teladoc Health's board of directors. Since taking the reins in 2009, he has led Teladoc Health to its position today as the world leader in virtual care, achieving significant growth in revenue, membership, and telehealth utilization. Under his leadership the company has established a proven track record of successfully shaping the market and driving healthcare transformation by executing on the strategic vision, delivering award-winning innovation, and effectively integrating each corporate acquisition.Nationally recognized as a thought leader and trailblazer in the virtual delivery of healthcare, Mr. Gorevic is fueled by a passion for improving healthcare outcomes and providing universal access to care. His extensive career in healthcare began at Oxford Health, and he has also held executive leadership roles at WellPoint, Inc. (now Anthem, Inc.) and Empire BlueCross BlueShield.He holds a Bachelor of Arts in International Relations from the University of Pennsylvania.
Massachusetts General Hospital
Read Bio ⟶Sharmin Ghaznavi, MD, PhD, is the Associate Director and the Director of Cognitive Neuroscience at the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital. Dr. Ghaznavi also serves as a psychiatrist at the MGH Dauten Family Center for Bipolar Treatment Innovation and is an instructor in Psychiatry at Harvard Medical School. Her research interests are the neural correlates of cognitive processes underlying mental illness. Dr. Ghaznavi has been the recipient of the Dupont-Warren and Livingston psychiatric research fellowships from Harvard Medical School and a 2012 NARSAD Young Investigator Award from the Brain and Behavior Research Foundation.
Dr. Ghaznavi received her undergraduate degrees in biology, brain and cognitive sciences, and philosophy from the Massachusetts Institute of Technology. She obtained her medical degree and PhD in neuroscience from Yale University and completed a residency in adult psychiatry at the Mass General/McLean Psychiatry Residency Program. As a resident, Dr. Ghaznavi received the Thomas P. Hackett award for academic and research excellence and the Joyce Tedlow Award from the mood and anxiety disorders board for efforts to integrate psychotherapy, psychopharmacology and research.
Wesana Health; Former NHL
Read Bio ⟶Daniel Carcillo is the CEO and Co-founder of Wesana Health, an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Prior to launching Wesana, Daniel was a professional hockey player who won two Stanley Cup Championships with the Chicago Blackhawks before being forced to retire at the age of 30 due to post-concussion syndrome. In the years following his professional hockey career, Carcillo has been steadfastly focused on researching and developing natural-sourced neurological treatment regimens to treat TBI. Daniel is a leading advocate for the emerging psychedelics space and sits on the board of the Heroic Hearts Project, a registered 501(c)(3) non-profit that connects military veterans struggling with mental trauma to psychedelic therapy options including ayahuasca, psilocybin and ketamine.
Apeiron Investment Group
Read Bio ⟶Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, his family office and asset management business. Apeiron’s areas of focus are Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has deep experience and a proven track record of more than 20 years. Apeiron has a global approach and deploys capital with a team of more than 20 investment professionals over seven strategies. As the investment group is investing predominantly its own capital, they are entrepreneurial, reliable & flexible, and a true, long term partner for all portfolio companies. Apeiron invests across the entire company lifecycle, starting from seed/startup investments to large-scale growth rounds as well as investments into listed companies.
CDC
Read Bio ⟶Rochelle P. Walensky, MD, MPH, is the 19th Director of the Centers for Disease Control and Prevention and the ninth Administrator of the Agency for Toxic Substances and Disease Registry. She is an influential scholar whose pioneering research has helped advance the national and global response to HIV/AIDS. Dr. Walensky is also a well-respected expert on the value of testing and treatment of deadly viruses.
Dr. Walensky served as Chief of the Division of Infectious Diseases at Massachusetts General Hospital from 2017-2020 and Professor of Medicine at Harvard Medical School from 2012-2020. She served on the frontline of the COVID-19 pandemic and conducted research on vaccine delivery and strategies to reach underserved communities.
Dr. Walensky is recognized internationally for her work to improve HIV screening and care in South Africa and nationally recognized for motivating health policy and informing clinical trial design and evaluation in a variety of settings.
She is a past Chair of the Office of AIDS Research Advisory Council at the National Institutes of Health, Chair-elect of the HIV Medical Association, and previously served as an advisor to both the World Health Organization and the Joint United Nations Programme on HIV/AIDS.
Originally from Maryland, Dr. Walensky received her Bachelor of Arts from Washington University in St. Louis, her Doctor of Medicine from the Johns Hopkins School of Medicine, and her Masters in Public Health from the Harvard School of Public Health.
NewYork-Presbyterian
Read Bio ⟶Steven J. Corwin, MD, is President and Chief Executive Officer of NewYork-Presbyterian, one of the nation’s largest, most comprehensive healthcare delivery systems.
Under Dr. Corwin’s leadership, NewYork-Presbyterian has nearly doubled in size and now comprises more than 47,000 employees and affiliated physicians, dedicated to providing world-class care during nearly 6 million patient visits each year at 10 hospitals as well as 200 primary and specialty care clinics and medical practices across the Greater New York area. Together with two distinguished medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, NewYork-Presbyterian provides high-quality, compassionate care, pursues clinical excellence, engages in pioneering medical research, and provides outstanding medical education to the next generation of doctors. NewYork-Presbyterian Hospital, the seven-campus academic medical center, is ranked No. 4 in the nation and has been the top-ranked hospital in New York for 20 consecutive years, according to U.S. News and World Report’s annual rankings of “Best Hospitals.”
As President and CEO, Dr. Corwin has embraced innovative approaches to patient-centered care. He led the way in establishing the NewYork-Presbyterian Regional Hospital Network and NewYork-Presbyterian Medical Groups, which enable patients to receive NewYork-Presbyterian’s world-renowned care in their own communities. He has launched a number of groundbreaking initiatives, including NYP OnDemand, a digital suite of telehealth services that increases access to NewYork-Presbyterian’s world-class care, and the East Coast’s first Mobile Stroke Treatment Unit, which provides fast, specialized care to patients who may be having a stroke and expanded this service to Brooklyn and Queens. He has also overseen the development of the NewYork-Presbyterian David H. Koch Center, a state-of-the-art ambulatory care facility that offers a patient experience that is second to none.
Healthcare quality has been a major focus of his tenure. For the third consecutive year, NewYork-Presbyterian Hospital is the only hospital in the nation with statistically better 30-day mortality rates in all six medical conditions measured by the Centers for Medicare and Medicaid Services (CMS). Those conditions are: heart failure, pneumonia, COPD, heart attack, stroke and coronary artery bypass graft.
Recognizing that engaging physicians is crucial to NewYork-Presbyterian’s success, Dr. Corwin has launched a series of initiatives to improve communication, address barriers to physician work, and encourage input from physicians on strategic development. He also launched the LEAD Attending Program (Leadership, Education and Development) for young attending physicians interested in careers that include healthcare administration.
He has championed a Respect initiative that encourages employees to work together as a team to provide the highest quality care to patients while also treating each other with respect and a Diversity and Inclusion initiative. As part of his commitment to employees, he instituted the most comprehensive paid parental leave policy of its kind among New York City hospitals and healthcare systems.
Prior to his appointment as CEO, Dr. Corwin served as NewYork-Presbyterian Hospital’s Executive Vice President and Chief Operating Officer, where he oversaw day-to-day operations across five campuses. Dr. Corwin joined the NewYork-Presbyterian team in 1979. From 1998 to 2005, he was the organization’s Senior Vice President and Chief Medical Officer.
Dr. Corwin is Immediate Past Chairman of the Health Care Systems Council of the American Hospital Association, Past Chairman of the Healthcare Association of New York State, and Past Chairman of the Greater New York Hospital Association. He remains on the board of each of these organizations and is a Board Member at the New York Academy of Medicine. In addition, he is a member of the Citizens’ Committee for Children of New York’s Corporate Advisory Council, the Association for a Better New York’s Census 2020 Committee, and a member of the Mayor’s Fund Board of Advisors. In 2020, the Foreign Policy Association awarded Dr. Corwin its highest honor, the Foreign Policy Association Medal, in recognition of his work to expand public knowledge of responsible internationalism. Also in 2020, Dr. Corwin was inducted into the Crain’s New York Business Hall of Fame.
A cardiologist and internist, Dr. Corwin obtained his undergraduate and medical degrees from Northwestern University, graduating summa cum laude and with Alpha Omega Alpha honors. He completed both his internal medicine residency and cardiology training at Columbia-Presbyterian Medical Center.
Centene Corporation
Read Bio ⟶Michael Neidorff is Centene Corporation's chairman, president and chief executive officer. A recognized leader in the industry, he is committed to building a multi-national healthcare enterprise while upholding Centene's local approach to healthcare. He demonstrates a history of successfully implementing programs and services under Medicaid, Medicare, and commercial managed care. Under his leadership, Centene has grown from a $40 million corporation to a publicly traded (NYSE: CNC), FORTUNE® 100, diversified, healthcare enterprise.
Michael Neidorff became president and chief executive officer of Centene Corporation in 1996. The company established operations in all 50 states – to become the largest Medicaid managed care organization in the U.S. and the top insurer in the Health Insurance Marketplace. Revenues are expected to exceed $114 billion in 2021. Centene now delivers high-quality and accessible healthcare to nearly 1 in 15 individuals across the nation.
Centene provides accessible, cost-effective coverage to the rising number of under-insured and uninsured people in communities across the U.S. Under Mr. Neidorff's leadership, Centene has expanded from operating Medicaid health plans solely in Wisconsin and Indiana, to operations in every state, serving more than 25 million managed care and TRICARE eligible individuals.
Mr. Neidorff's record of transformative leadership is proven in the healthcare industry. In 1985, he started Physicians Health Plan of Greater St. Louis, a subsidiary of UnitedHealth Group. He served as the president and chief executive officer from 1985-1995, and grew the plan to be one of UnitedHealth Group's most successful and profitable plans in the country. From 1995-1996, he served as the regional vice president of Coventry Health Care, Inc., a publicly traded managed care organization, and as the president and chief executive officer of one of its subsidiaries, Group Health Plan Inc. in St. Louis. He also served in international senior executive positions at Miles Laboratories/Bayer AG.
Michael Neidorff dedicates significant time to civic organizations. He is a board member of the National Urban League and served as its chairman from 2014-2019. In 2015, he was inducted into the Hall of Fame for Junior Achievement of Greater St. Louis. He served as a member of the board of directors for the Greater St. Louis Boy Scouts of America since 1990, serving as Pathfinder district chair, vice chairman and chairman of the Special Needs Committee, vice president of Finance, and council president. Mr. Neidorff is a member of the board of trustees for Trinity University in San Antonio, Texas, his alma mater, and previously served as chairman of the board.
Community Involvement and Recognition
Having an appreciation for the arts, Mr. Neidorff is also involved with several major arts institutions. He sits on the board of the St. Louis Symphony Orchestra, where he previously served a term as chairman and is currently a trustee on its Endowment Committee. As a trustee for the Opera Theatre of St. Louis, he serves on the Institutional Development Committee and previously served as a vice chairman. Mr. Neidorff serves as Treasurer of the John F. Kennedy Center for the Performing Arts Board of Trustees and member of the International Committee on the Arts. He previously served the Kennedy Center as a 2005 trustee, vice chairman of its Fund Board, chairman of the Education Committee, and co-chair of the International Committee on the Arts.
Michael Neidorff has been recognized by multiple organizations for his business leadership as well as his community and civic involvement. He was named one of the "100 Most Influential People in Healthcare" by Modern Healthcare magazine in 2018 and 2019. In January 2020, he and his wife, Noémi Neidorff, received the Whitney M. Young Humanitarian Award from the Urban League of Metropolitan St. Louis and Saint Louis University. In 2019, he was honored at the St. Louis Business Journal's C-Suite Awards for his contributions to business and the St. Louis community. He was honored with the St. Louis Post-Dispatch Citizen of the Year Award in 2017.
Mr. Neidorff holds a bachelor's degree from Trinity University and a master's degree from St. Francis College. He lives in St. Louis, with his wife, Noémi. They have two children.
Vir Biotechnology and Denali Therapeutics
Read Bio ⟶Vicki Sato, Ph.D., serves as chairman of the board of directors at Vir Biotechnology and Denali Therapeutics. She is a business advisor to enterprises in the biotechnology and pharmaceutical industries. From 2006-2017, Dr. Sato served on the faculties of Harvard University: as Professor of Management Practice at The Harvard Business School and as Professor of the Practice, Molecular and Cell Biology, on the Faculty of Arts and Sciences.
Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs in the areas of virology, inflammation and cystic fibrosis. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and where she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board.
In addition to chairing the boards of Denali Therapeutics and Vir Biotechnology, Dr. Sato serves as a member of the board of directors of publicly held Akouos. She has previously served on the boards of Bristol Myers Squibb, where she served as lead independent director, BorgWarner Corporation, PerkinElmer Corporation, Alnylam, and Syros Pharmaceuticals. In 2018, she was the recipient of an Outstanding Director award from the National Association of Corporate Directors. Dr. Sato is a member of the Board of Advisors of the Isabella Stewart Gardner Museum in Boston, MA, and Co-Chairs the Advisory Council on LifeSciences for the New York City Economic Development Council.
She received her A.B. from Radcliffe College and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California, Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
CNBC
Read Bio ⟶Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
CNBC
Read Bio ⟶Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
CNBC
Read Bio ⟶Tyler Mathisen co-anchors CNBC's "Power Lunch" (M-F, 1PM-3PM ET), one of the network's longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network's events team to grow the rapidly expanding business.
Previously, Mathisen was co-anchor of "Nightly Business Report," an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network's daily content and coverage. He was also co-anchor of CNBC's "Closing Bell."
Mathisen has reported one-hour documentaries for the network including "Best Buy: The Big Box Fights Back," "Supermarkets Inc: Inside a $500 Billion Money Machine" and "Death: It's a Living." Mathisen was also host of the CNBC series "How I Made My Millions."
Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine's mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.
In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on "Caring for Aging Parents," which aired on ABC's "Good Morning America." Mathisen served as money editor of "GMA" from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York's WCBS-TV.
A native of Arlington,Va., Mathisen graduated with distinction from the University of Virginia.
12:00pm EST
Transforming Health Care
At the forefront of developing Covid-19 antibodies, Eli Lilly has doubled down on R&D, digital analytics and medical innovation. With a pipeline of new drugs in the works to treat conditions ranging from Alzheimer’s to diabetes to migraines, they are focusing hard on finding new ways to collaborate with partners and governments to deliver groundbreaking treatments in record time.
David Ricks, Eli Lilly Chairman and CEO
Behind the Scenes of Developing Vaccines
Pfizer turned the impossible into possible, creating a groundbreaking Covid-19 vaccine in record time. Leading the charge was Kathrin Jansen, who will take us behind-the-scenes of this massive undertaking and share lessons in efficiency and leadership.
Kathrin Jansen, Pfizer SVP, Head of Vaccine R&D
Innovative Thinking to Fight Inequality
The toll of the pandemic is nowhere clearer than inside the halls of MLK Community Hospital, which serves the most economically depressed people in Covid-ravaged Los Angeles. One visionary hospital leader is taking a page out of Silicon Valley and using innovation to put an end to unequal systems of care.
Dr. Elaine Batchlor, Martin Luther King, Jr. Community Hospital CEO
Mission Critical: Mental Health Care
When Centene announced its purchase of Magellan Health earlier this year, it established one of the nation’s largest behavioral health platforms in the country, providing a critical service to many who are on government-sponsored health care. With a burgeoning mental health crisis upon us, we’ll discuss why adding digital tools is crucial for patient care, and how it could set the standard going forward.
Michael Neidorff, Centene CEO
Breakout Sessions
Details TBA
Magic Mushrooms for Mental Health
Psychedelics have been highly stigmatized, and highly restricted, for nearly a century. Now, renewed interest has given way to robust research, to identify their potential as treatment for conditions like depression, addiction, and trauma. One former NHL star shares his personal story of transformation. And we’ll examine whether psychedelics have the potential to go mainstream and disrupt the drug industry.
Daniel Carcillo, Wesana Health CEO, Former NHL Player
Christian Angermayer, Apeiron Investment Group Founder
Dr. Sharmin Ghaznavi, Mass General Hospital Assoc. Director, Center for the Neuroscience of Psychedelics
Investor’s Playbook: Game-Changing Startups
At the height of the pandemic, the biotech industry saw an unprecedented level of investment activity. And there is no sign of a slowdown. Former Google Ventures CEO Bill Maris gives us a peek at his playbook and explains which disruptive life science technologies – from microsurgical robotics and precision medicines to genomics and therapeutics– are successfully tackling humanity’s most complex conditions.
Bill Maris, Section 32 Founder
Health Equity for All
The Covid-19 pandemic exposed a wide array of racial and socio-economic disparities in health care. We’ll examine one New York hospital on the front lines as a case study, reflect on the lessons learned, and discuss actionable steps every provider should take now to move toward a more equitable future.
Dr. Steven Corwin, NewYork-Presbyterian Hospital CEO
Dr. Julia Iyasere, NewYork-Presbyterian Dalio Center for Health Justice Vice President
The Future of Medicine: Telehealth
The boom of phone and video appointments during the pandemic ushered in a new era of telemedicine. We’ll discuss the rapid rise with the most dominant player in the industry and examine how telemedicine will evolve post-Covid.
Jason Gorevic, Teladoc CEO
4:00pm ET
Change Healthcare is a leading independent healthcare technology company, focused on insights, innovation and accelerating the transformation of the healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.
Our platform and comprehensive suite of software, analytics, technology enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience.
Our Intelligent Healthcare Network is one of the largest clinical and financial healthcare networks in the U.S., facilitating over 15 billion transactions and approximately $1.5 trillion in adjudicated claims, or more than one-third of all U.S. healthcare expenditures. Our customer base includes approximately 2,400 government and commercial payer connections, 1,000,000 physicians, 125,000 dentists, 39,000 pharmacies, 6,000 hospitals and 700 laboratories.
Ontrak is a leading AI and telehealth enabled behavioral health company with programs that leverage advanced analytics combined with human connection to identify, engage, guide-to-treatment and activate complex, hard-to-reach populations with unaddressed behavioral conditions and co-existing chronic medical conditions. Ontrak offers up to 52 weeks of a coach-driven, therapist-led behavior change program that engages members using an evidence-based, whole-person approach, delivering durable outcomes and validated cost savings to healthcare payers.
Visit www.ontrak-inc.com.
Pfizer
Albert Bourla is Chairman and CEO of Pfizer.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Epic
Judith Faulkner is Founder and CEO of Epic Systems Corporation.
The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Moderna
Stéphane Bancel is Chief Executive Officer of Moderna.
Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Merck
Julie Louise Gerberding is EVP and Chief Patient Officer at Merck.
Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Bristol Myers Squibb
Giovanni Caforio, M.D. is Chairman of the Board and CEO of Bristol Myers Squibb.
Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Regeneron Pharmaceuticals
Leonard Schleifer is Founder, President and CEO of Regeneron Pharmaceuticals.
Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Biomatics Capital
Julie Sunderland is Managing Director of Biomatics Capital.
Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.
Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.
Verily Life Sciences
Jessica L. Mega, M.D., M.P.H, is Chief Medical Officer at Verily Life Sciences.
Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.
GSK
Hal Barron is Chief Scientific Officer and President, R&D at GSK.
Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Fmr. U.S. Food and Drug Administration
Dr. Gottlieb is the former Commissioner of the U.S. Food and Drug Administration and a CNBC Contributor.
Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Komodo Health
Arif Nathoo, M.D. is Co-founder & CEO at Komodo Health.
Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
Sanofi
John C. Reed, M.D., PhD., is EVP, Global Head of Research & Development at Sanofi.
John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.
In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.
John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.
He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.
BD (Becton, Dickinson and Company)
Tom Polen is CEO and President of BD (Becton, Dickinson and Company).
Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.
Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.
In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.
In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.
Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
Scripps Research Translational Institute
Eric Topol is Founder and Director of the Scripps Research Translational Institute.
Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.
Pfizer
Read Bio ⟶As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.
Epic
Read Bio ⟶The developer of a comprehensive, patient-centric electronic medical record (EMR) system and founder of Epic Systems Corporation, Judith Faulkner is recognized for her scientific and technological leadership. Her vision for health care technology is both comprehensive and simple: provide the relevant medical information when it's needed, do what's best for the patient, and help clinicians collaborate. Her innovative health information technology infrastructure allows for the implementation of workflow steps, clinical guidelines, and best-practice alerts tailored to each clinician's role in patient care while on the patient end providing information regarding prescriptions, appointments, communication with the care team, and prevention/treatment reminders.
Epic EMR systems do away with traditional paper files and provide a single, shared patient record which can be accessed by clinical staff across all manner of health care services and, with proper consent, across different health care organizations. Given the complexity and magnitude of medical data that may be included, the technological challenge has been to develop this comprehensive infrastructure for diverse health care settings while scaling to millions of records and thousands of concurrent users who all require rapid response times.
Independent studies have documented the positive impact of Epic technologies on the quality of clinical care and the software has led to improvements in medical research. To date, 240 health care organizations use Epic technologies to provide medical care to approximately 118 million people. This includes fourteen Wisconsin organizations that increasingly serve as the early adopters of the latest advances in Epic's health technologies.
Faulkner has led Epic strategically and operationally to create state-of-the-art technologies that improve the quality, safety, and efficiency of health care across Wisconsin, the United States, and, increasingly, the world.
Moderna
Read Bio ⟶Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.
Mr. Bancel currently serves on the board of directors of Qiagen N.V. and previously served on the board of directors of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.
Merck
Read Bio ⟶Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer at Merck & Co., Inc., where she is responsible for a broad portfolio focused on patient engagement, strategic communications, global public policy, population health and corporate responsibility. She joined Merck in 2010 as president of Merck vaccines
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through 40+ emergency responses to public health crises. She serves on the Boards of Biotechnology Innovation Organization (BIO), Cerner Corporation and the MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries.
Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. In 2018, she was selected as the Healthcare Businesswomen Association’s Woman of the Year and received the Lifetime Achievement Award from eyeforpharma.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine. Dr. Gerberding received a Masters of Public Health at the University of California, Berkeley. She is a member of the National Academy of Medicine and a fellow of the Infectious Diseases Society of America and the American College of Physicians. She is board certified in Internal Medicine and Infectious Diseases.
Bristol Myers Squibb
Read Bio ⟶Giovanni Caforio, M.D., is Chairman of the Board and chief executive officer of Bristol Myers Squibb. Under Giovanni’s leadership, BMS is delivering innovative medicines to treat patients with cancer, auto-immune diseases and cardiovascular disease, and is advancing one of the most diverse and promising pipelines in the industry. Giovanni leads a diverse global workforce dedicated to the company’s mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
Giovanni was appointed CEO in 2015 and elected as Chairman of the Board of Directors in 2017. As part of Bristol Myers Squibb’s strategy to combine the agility of a biotech with the reach and scale of an established pharma company, Giovanni led the company’s acquisition of Celgene in 2019. Today the company is a leading biopharma company focused on transforming patients’ lives through science. He has developed a strong patient-focused culture, with teams who are passionate about the work they do to help address some of the most challenging diseases of our time. He has led BMS’ drive to promote an inclusive culture where employees are encouraged to challenge the status quo and bring forward solutions.
Giovanni is an active champion for a policy environment that values healthcare innovation and supports patient access to medicines. Reflecting his advocacy, in 2015 he joined the Board of Directors for the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and in 2019 was named Chairman.
Prior to becoming CEO, Giovanni served as chief operating officer with responsibility for leading a fully integrated worldwide commercial organization and the companywide functions of Enterprise Services and Global Manufacturing & Supply. This was preceded by appointment as the company’s chief commercial officer.
Born and educated in Italy, Giovanni received his medical doctorate from the University of Rome. He started his career with Abbott Laboratories before joining Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. Giovanni advanced through a series of regional European management positions and, in 2004, became senior vice president, European Marketing and Brand Commercialization. In 2007, he relocated to the U.S. as senior vice president, U.S. Oncology. He was named senior vice president, Global Commercialization, Oncology and Immunology in 2010, then became president of the company’s U.S. organization in 2011.
Regeneron Pharmaceuticals
Read Bio ⟶Leonard S. Schleifer, MD, PhD, founded Regeneron Pharmaceuticals in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College. Leveraging a lifelong passion for science and an entrepreneurial spirit, he has served as a director, its president and chief executive officer since its inception and acted as chairman of the board from 1990 through 1994. Schleifer received his MD and PhD in Pharmacology from the University of Virginia, and he is a licensed physician certified in neurology by the American Board of Psychiatry and Neurology.
Biomatics Capital
Read Bio ⟶Prior to co-founding Biomatics Capital Partners in 2016, Ms. Sunderland was director of Program Related Investments for the Bill & Melinda Gates Foundation. She led the foundation’s $1.5 billion strategic investment pool, which focused on global health, global development and education. She funded 50 investments, including 30 in health care, and built a team of 10 investment professionals.
Ms. Sunderland also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.Ms. Sunderland holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies.
Ms. Sunderland sits on the Board of Directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana.
Verily Life Sciences
Read Bio ⟶Jessica L. Mega, M.D., M.P.H., is the Chief Medical Officer at Verily Life Sciences. As CMO, Mega’s focus is on translating scientific insights and technological innovations into partnerships and programs that improve patient outcomes. She oversees all of Verily’s clinical research efforts, including the Baseline Study.
GSK
Read Bio ⟶Hal joined GSK in January 2018 as Chief Scientific Officer and President, R&D, responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is an Executive Director of the GSK Board and a member of the Corporate Executive Team.
His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.
Fmr. U.S. Food and Drug Administration
Read Bio ⟶Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Komodo Health
Read Bio ⟶Arif Nathoo, M.D., is co-founder & chief executive officer at Komodo Health where he oversees data sciences, engineering, and product development initiatives for the company. He has spent the past 15 years in healthcare and life sciences leadership roles. Before Komodo Health, Arif was a leader in McKinsey’s Healthcare practice where he was responsible for helping enterprise healthcare address issues in corporate strategy, finance, sales and marketing, and organization building. He co-led McKinsey’s Medical Affairs Practice, which created analytic products and services to improve non-promotional engagement between industry and providers.
He has conducted research in novel instructional technologies and medical devices, with multiple publications in peer-reviewed journals. Arif graduated magna cum laude with Highest Honors from Harvard University with an A.M. in molecular and cellular biology, an M.D. from Harvard Medical School, and M.P.A. in health policy from Harvard Kennedy School.
Sanofi
Read Bio ⟶John Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.
He began his academic career as a member of the faculty at the University of Pennsylvania in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. John Reed subsequently held faculty appointments at several universities including the University of California, the University of Florida and ETH-Zurich.
In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California, one of the largest independent non-profit biomedical research institutes in the United States. From 2002 to 2013, he served as CEO of the Institute. During his tenure, John Reed ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants, and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research.
John Reed has served on multiple editorial boards of research journals, and was scientific founder or co-founder of four biotechnology companies. He has served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations.
From 2013 to 2018, John Reed was Global Head of Roche Pharmaceutical Research & Early Development, based at company headquarters in Basel, Switzerland. He was responsible for research through Phase IIb development for all therapeutic areas, overseeing R&D activities across 7 global sites.
He assumed his current position as Executive Vice President, Global Head of Research & Development for Sanofi in July 2018.
BD (Becton, Dickinson and Company)
Read Bio ⟶Tom Polen serves as chief executive officer and president of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. He also leads the BD Executive Leadership Team.
Polen joined BD in 1999, after growing an early phase start-up that was subsequently purchased by BD. From 1999 to 2004, he held a variety of sales and marketing positions with increasing responsibility, in BD Biosciences and BD Diagnostics Systems.
In 2004, Polen joined Baxter Healthcare, where he led the pharmaceutical manufacturing and services business before assuming the role of vice president of Strategic Marketing. He was later promoted to general manager of Baxter’s Injectable Pharmaceuticals business. During his tenure at Baxter, Polen was named among Chicago’s top 40 leaders under 40, by Crain’s Chicago Business.
In 2009, Polen rejoined BD as president of BD Preanalytical Systems. He assumed the role of president of BD Diagnostics Systems from 2010 to 2013, and later served as group president, responsible for BD Medical Surgical Systems and BD Pharmaceutical Systems. In 2014, Polen was named segment president, BD Medical, where he led the $12 billion acquisition of CareFusion in 2015, the company’s expansion into informatics and digital health solutions and the $24 billion acquisition of C. R. Bard, Inc. in 2017. Following the Bard acquisition, Polen was named president and chief operating officer in 2017 where he was responsible for the company’s three business segments – Medical, Life Sciences and Interventional, as well as Research and Development, Innovation, Operations and the commercial organization of the company’s Americas Region.
Polen is an active benefactor and volunteer for the Children’s Tumor Foundation, as well as a number of national and local associations committed to helping patients with breast cancer. He earned his bachelor’s degree from the Salisbury University of Maryland and a master’s degree in business administration from Johns Hopkins University.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com
Scripps Research Translational Institute
Read Bio ⟶Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 270,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.
In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.
;)
Relive some of the biggest moments from the Healthy Returns Virtual Summit
Open Video
How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open Video
Top health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open VideoRelive some of the biggest moments from the Healthy Returns Virtual Summit
Open VideoHow innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
Open VideoTop health care investors, CEOs and technologists explore the innovations that will drive better outcomes, financially and clinically.
Open Video